SCP Health Expands Performance Edge Model to Strengthen Hospital-Based Care Hospitals across the United States are navigating an increasingly complex healthcare environment marked by workforce shortages, financial pressures, and rising administrative demands. In response to these challenges, SCP Health, a…
RefleXion Expands Medicare Reimbursement for SCINTIX Therapy Across Majority of U.S. Regions RefleXion Medical has announced a significant advancement in expanding access to its innovative SCINTIX® autonomous radiotherapy, as another Medicare Administrative Contractor (MAC), Noridian Healthcare Solutions, LLC, has approved…
Zentist to Host Dental RCM Bootcamp 6.0 in Nashville, Bringing Together Industry Leaders for Advanced Revenue Cycle Insights Zentist has officially announced that its highly anticipated Dental RCM Bootcamp 6.0 will take place from August 30 to September 1, 2026,…
Cencora to Release Second Quarter Fiscal 2026 Results on May 6, 2026 Cencora, Inc. has officially announced the date and time for the release of its financial results for the second quarter of fiscal year 2026. The company will publish…
Alpha Cognition Secures U.S. Patent for ALPHA-1062 in Traumatic Brain Injury, Expanding Pipeline Potential Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The…
Alto Neuroscience Shares Phase 2 Results for ALTO-101 and Refocuses Pipeline Strategy Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company dedicated to developing precision medicines for neuropsychiatric disorders, has released topline findings from its Phase 2 proof-of-concept (POC) study evaluating ALTO-101.…
Premier Radiology Services Acquires Global Imaging Solutions to Expand Teleradiology and Subspecialty Expertise Premier Radiology Services (Premier) has announced the acquisition of Global Imaging Solutions (GLOBIS), a well-established teleradiology provider known for delivering subspecialty imaging interpretations to outpatient imaging centers…
FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its…
Shionogi Strengthens Rare Disease Portfolio with Full Acquisition of RADICAVA (Edaravone) Shionogi & Co., Ltd. has officially completed the acquisition of all rights to RADICAVA (edaravone), marking a major milestone in the company’s strategic expansion into rare diseases. The transition…
Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd. for its novel oncology candidate FMC-220, a first-in-class covalent activator…